RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Clinical trials for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOBLASTOMA, IDH-WILDTYPE trials appear
Sign up with your email to follow new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New brain cancer combo seeks safe dose in early trial
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of an experimental drug called triapine when given with radiation therapy. It's for adults whose glioblastoma or astrocytoma brain tumors have returned after previous treatment. The main goal is to find out if the combina…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 22:55 UTC
-
New Two-Drug attack on deadly brain cancer
Disease control Recruiting nowThis study is testing a new combination of two immunotherapy drugs, efineptakin alfa and pembrolizumab, for adults whose aggressive brain cancer (glioblastoma) has come back. The goal is to see if giving these drugs before and after surgery helps the immune system fight the cance…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Direct-to-Brain attack: new combo targets deadly recurrent tumor
Disease control Recruiting nowThis early-stage study is testing the safety and effectiveness of a two-part immunotherapy for adults whose aggressive brain cancer (glioblastoma) has returned after initial treatment. After surgery to remove the main tumor, a special combination of two drugs is delivered directl…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Darell Bigner • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Experimental cell therapy targets deadly recurrent brain cancer
Disease control Recruiting nowThis study is testing an experimental cell therapy called P134 for adults whose aggressive brain cancer (glioblastoma) has come back. Doctors will give patients modified immune cells (CAR-T cells) designed to target the tumor and see if it is safe and can help control the cancer.…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Fat cells fight brain cancer: new stem cell trial offers hope
Disease control Recruiting nowThis early-stage trial is testing whether stem cells from donated body fat can be safely injected into the brain during surgery to treat aggressive brain cancer that has returned. The study aims to find the safest dose and see if these cells can slow tumor growth and improve surv…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC